Hypogonadism Primary vs Secondary: Causes, Diagnosis, and Treatment

What Is Hypogonadism and Why Does the Distinction Matter?

Hypogonadism means the testes produce insufficient testosterone, sperm, or both. The distinction between primary and secondary forms is not academic: it changes the diagnostic workup, the choice of treatment, and whether fertility can realistically be preserved. A man with secondary hypogonadism caused by a pituitary adenoma needs an MRI and tumor management, not just a testosterone prescription. A man with primary hypogonadism from Klinefelter syndrome cannot recover natural testosterone production regardless of which pituitary hormones are supplemented.

The Endocrine Society's 2018 Clinical Practice Guideline defines male hypogonadism as "a clinical syndrome that results from failure of the testes to produce physiological concentrations of testosterone and/or a normal number of spermatozoa due to disruption of one or more levels of the hypothalamic-pituitary-testicular (HPT) axis." [1] That three-level axis, hypothalamus releasing GnRH, pituitary releasing LH and FSH, and testes responding with testosterone and sperm, is where the two subtypes diverge.

Prevalence data from the Endocrine Society estimate that 2 to 4% of men carry a biochemical diagnosis, yet symptomatic hypogonadism goes unrecognized in a far larger share of the male population. [1] Two fasting, morning total testosterone values below 300 ng/dL, confirmed on separate days, anchor the biochemical diagnosis before any subtyping begins. [1]

Primary Hypogonadism: Testicular Failure With Elevated Gonadotropins

Primary hypogonadism means the testes have lost the capacity to respond to LH and FSH. The pituitary ramps up both gonadotropins trying to stimulate the testes. Those hormones rise. Testosterone stays low. This hormonal pattern, high LH, high FSH, and low testosterone, is the biochemical fingerprint clinicians look for first.

Common causes include:

• Klinefelter syndrome (47,XXY), the most frequent genetic cause, present in roughly 1 in 650 male births [2]
• Bilateral orchitis (mumps-related or autoimmune)
• Testicular torsion with ischemic damage
• Chemotherapy or radiation to the gonads
• Cryptorchidism (undescended testes) not corrected early
• Trauma or surgical orchiectomy

Klinefelter syndrome deserves particular attention. A 2020 review in Genetics in Medicine noted that fewer than 25% of affected men receive a diagnosis during their lifetime, meaning a large number of men on TRT for "idiopathic" primary hypogonadism may carry an undetected chromosomal variant. [2] Free testosterone and sex-hormone-binding globulin (SHBG) should be checked alongside total testosterone because SHBG elevation, common in Klinefelter, artificially inflates total testosterone readings while free hormone remains insufficient. [3]

Because the defect is in the testes themselves, no amount of GnRH or gonadotropin therapy restores endogenous testosterone production in most primary cases. Testosterone replacement therapy is the definitive treatment. Fertility options, if desired, require specialist-led sperm retrieval techniques rather than hormonal stimulation alone. [1]

Secondary Hypogonadism: Signaling Failure From the Brain

Secondary hypogonadism is a dysfunction of the hypothalamus or pituitary. The testes are capable of producing testosterone but never receive an adequate signal to do so. Laboratory values show low testosterone alongside LH and FSH that are low or inappropriately normal rather than compensatorily elevated.

The Endocrine Society guideline specifies that clinicians "measure LH and FSH to distinguish primary from secondary hypogonadism in all men with documented testosterone deficiency." [1] That single additional step directs the entire workup that follows.

Causes divide into organic and functional:

Organic causes include pituitary adenomas (prolactinomas being the most common secretory type), Kallmann syndrome (GnRH deficiency with anosmia), hemochromatosis depositing iron in gonadotroph cells, prior traumatic brain injury, and prior cranial radiation.

Functional causes are more prevalent in clinical practice. Obesity is the largest driver: adipose tissue converts testosterone to estradiol via aromatase, and excess estradiol feeds back to suppress GnRH and LH secretion. [4] A 2008 cross-sectional study in Diabetes Care (N=2,165) found that obese men had 2.4-fold higher odds of low testosterone compared with normal-weight men, almost entirely through the functional secondary pathway. [4] Chronic opioid use suppresses GnRH in a dose-dependent manner, affecting an estimated 86% of men on long-term opioid therapy. [5] Hyperprolactinemia, whether from a pituitary tumor or from antipsychotic medications, inhibits GnRH pulsatility and reliably suppresses testosterone. [6]

Because the testes retain function, secondary hypogonadism from functional causes can be partially or fully reversed. Weight loss of 10% body weight in obese men restores testosterone by an average of 2.9 nmol/L per a 2019 meta-analysis in European Journal of Endocrinology. [7] When the cause is a prolactinoma, dopamine-agonist therapy with cabergoline or bromocriptine frequently normalizes testosterone without any exogenous testosterone at all. [6]

Late-Onset Hypogonadism and Andropause

Late-onset hypogonadism (LOH) is a clinical syndrome specific to aging men and sits partly in the secondary category. The American Urological Association defines it as symptomatic testosterone deficiency in men over 40 who have no prior diagnosis of hypogonadism and no identifiable organic cause. [8]

Testosterone declines at roughly 1 to 2% per year after age 30. [9] By the seventh decade, 20 to 30% of men meet biochemical criteria for low testosterone, though only a fraction have symptoms severe enough to warrant treatment. [9] The European Male Aging Study (N=3,369) established that three sexual symptoms, reduced morning erections, reduced sexual thoughts, and erectile dysfunction, combined with total testosterone below 11 nmol/L (317 ng/dL) and free testosterone below 220 pmol/L, best predicted a clinical diagnosis of LOH. [10]

The term "andropause" draws an analogy to menopause, but the analogy has limits. Unlike menopause, testosterone decline in men is gradual, not abrupt, and gonadotropin elevation is modest rather than dramatic. Comorbidities including obesity, type 2 diabetes, and sleep apnea accelerate the decline through functional secondary mechanisms layered on top of age-related primary testicular senescence. [9] Treating those comorbidities first, before initiating TRT, may restore testosterone to acceptable levels without lifelong exogenous hormone use.

Diagnosing Hypogonadism: The Step-by-Step Workup

A correct diagnosis requires more than a single testosterone value. Below is the standard sequence used by most endocrinology and urology practices aligned with Endocrine Society and AUA guidance.

Step 1: Two morning fasting total testosterone measurements. Both must be below 300 ng/dL on separate occasions. [1]

Step 2: LH and FSH. High gonadotropins point to primary hypogonadism. Low or normal gonadotropins point to secondary hypogonadism. [1]

Step 3: Free testosterone and SHBG. Men with borderline total testosterone and elevated SHBG (common in aging, liver disease, and hyperthyroidism) may have clinically significant free testosterone deficiency not captured by total testosterone alone. [3]

Step 4: Prolactin. Elevated prolactin in any man with secondary hypogonadism mandates pituitary MRI. [6]

Step 5: Iron studies and ferritin to screen for hemochromatosis in secondary cases with no other obvious etiology.

Step 6: Karyotype when primary hypogonadism is diagnosed and no other cause is apparent, to detect Klinefelter syndrome. [2]

Step 7: Semen analysis if fertility matters to the patient. This step is often skipped in primary care but changes the treatment path substantially.

A morning draw before 10 a.m. is important because testosterone follows a diurnal rhythm, peaking in early morning and falling by 20 to 30% by mid-afternoon. [1] Phlebotomy after noon routinely generates falsely low values that trigger unnecessary workups.

TRT for Fatigue: What the Evidence Actually Shows

Fatigue is among the most common presenting symptoms of hypogonadism, yet it is also among the least specific. Thyroid disease, anemia, obstructive sleep apnea, depression, and iron deficiency all cause fatigue, and ruling them out before attributing fatigue to low testosterone prevents unnecessary TRT.

When hypogonadism is confirmed, the evidence for TRT improving fatigue is meaningful. The TRAVERSE trial, a randomized controlled trial of testosterone undecanoate in 5,204 men with hypogonadism and cardiovascular risk factors, reported statistically significant improvements in energy and vitality scores in the testosterone arm versus placebo at 12 months. [11] A 2016 New England Journal of Medicine testosterone trials report (the "T-Trials," N=790 men, average age 72) found that testosterone treatment produced a significant improvement in self-reported energy on the SF-36 vitality subscale, with a mean difference of 4.8 points. [12]

The improvement in fatigue correlates with testosterone normalization rather than with absolute dose. Men who reach mid-normal range testosterone levels, roughly 500 to 700 ng/dL, generally report better outcomes than those pushed to supraphysiologic levels, which may worsen sleep apnea and paradoxically increase fatigue through REM suppression. [13]

TRT for Low Libido: Mechanisms and Clinical Outcomes

Libido is directly androgen-dependent. Testosterone acts on androgen receptors in the limbic system, particularly the medial preoptic area of the hypothalamus, to generate sexual motivation. [14] Low testosterone is one of the most biochemically consistent causes of low libido in men, distinct from erectile dysfunction, which has a larger vascular and neurological component.

The T-Trials sexual function substudy (N=470) showed that testosterone increased sexual desire compared with placebo, with a standardized mean difference of 0.58, a moderate-to-large effect by Cohen's conventions. [12] Men with baseline testosterone below 230 ng/dL showed the largest libido response; those with baseline levels above 300 ng/dL showed minimal additional benefit. [12]

Onset of libido improvement on TRT is typically 3 to 6 weeks after treatment initiation. [15] Formulation affects onset speed. Testosterone cypionate 200 mg/mL injected intramuscularly every two weeks produces supraphysiologic peaks at 48 to 72 hours followed by troughs below baseline just before the next injection, a roller-coaster pattern that some men experience as inconsistent libido. [15] Weekly injections of 100 mg or twice-weekly injections of 50 mg produce steadier serum levels and more consistent libido. [15] Transdermal gels (1.62% testosterone gel, target dose 40.5 to 81 mg/day) achieve stable steady-state levels within 72 hours and avoid the peak-trough variability. [16]

TRT for Erectile Dysfunction: What Testosterone Can and Cannot Fix

Erectile dysfunction and low libido are distinct problems with overlapping causes. Erections depend primarily on nitric oxide-mediated vasodilation in the corpus cavernosum, a process modulated by but not solely driven by testosterone. [17]

A 2016 meta-analysis in The Journal of Sexual Medicine (17 RCTs, N=1,473) found that TRT improved erectile function scores on the International Index of Erectile Function (IIEF) by a mean of 3.0 points versus placebo, a statistically significant but clinically modest improvement. [17] For context, PDE5 inhibitors such as sildenafil or tadalafil improve IIEF scores by 6, 8 points in the same population. [17]

The clinical implication: TRT alone rarely resolves ED completely. Combination therapy, testosterone normalization plus a PDE5 inhibitor, produces substantially better outcomes in men with concurrent hypogonadism and vasculogenic ED. A 2017 paper in European Urology demonstrated that men with testosterone below 10.4 nmol/L who failed sildenafil 100 mg showed a 63% response rate after testosterone replacement was added. [18] This is a clinically meaningful finding: checking testosterone in men who do not respond to PDE5 inhibitors is a standard-of-care recommendation in the AUA erectile dysfunction guideline. [8]

The HealthRX clinical decision framework for men presenting with both low libido and ED: confirm hypogonadism biochemically first, initiate TRT, reassess erectile function at 8 to 12 weeks, and add a PDE5 inhibitor if erections remain inadequate despite testosterone normalization. Do not prescribe TRT solely for ED in men with normal testosterone, as the evidence for benefit in eugonadal men is weak. [17]

Treatment Options: Formulations, Doses, and Monitoring

Once the decision to treat is made, selecting the right formulation involves balancing convenience, cost, fertility goals, and the patient's ability to self-administer.

Injectable testosterone esters remain the most cost-effective option. Testosterone cypionate or enanthate, 100 to 200 mg intramuscularly every 1 to 2 weeks, costs under $30/month as a generic. [16] Testosterone undecanoate (Aveed) 750 mg IM every 10 weeks provides very stable levels but requires in-office administration under a REMS program due to rare pulmonary oil embolism. [19]

Transdermal gels (AndroGel 1.62%, Testim, Vogelxo) deliver 40.5 to 81 mg per day with good tolerability but carry a transfer risk to female partners and children. [16] Patients must apply to non-genital skin, allow drying, and avoid skin-to-skin contact for several hours. [16]

Subcutaneous testosterone pellets (Testopel) are implanted every 3 to 6 months, releasing testosterone steadily. Pellet dosing ranges from 150 mg to 900 mg depending on body weight and clinical response. Infection rates at implant sites run approximately 1 to 2%. [20]

Monitoring after TRT initiation per Endocrine Society guidance includes total testosterone at 3 months (target 400 to 700 ng/dL mid-range), hematocrit to screen for erythrocytosis (hold or reduce dose if hematocrit exceeds 54%), PSA at baseline and 3 to 12 months, and bone density if osteoporosis is a concern. [1] Men wishing to preserve fertility should not receive TRT; instead, clomiphene citrate 25 mg daily or hCG 1,500, 3 to 000 IU three times per week stimulates endogenous testosterone in secondary hypogonadism without suppressing spermatogenesis. [1]

Cardiovascular Safety: The TRAVERSE Trial Data

Concerns about cardiovascular risk from TRT dominated clinical practice after a 2010 NEJM trial was halted early. The TRAVERSE trial was specifically designed to resolve that question. Published in 2023 in The New England Journal of Medicine, TRAVERSE enrolled 5,204 men aged 45, 80 with hypogonadism and established or high risk for cardiovascular disease, randomized to testosterone undecanoate 200 mg/mL or placebo, with a median follow-up of 33 months. [11]

The primary endpoint, a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke, occurred in 7.0% of the testosterone group versus 7.3% of the placebo group (hazard ratio 0.96; 95% CI 0.78, 1.17), meeting the pre-specified non-inferiority margin. [11] The FDA reviewed this data and updated labeling to reflect that TRT does not increase MACE risk in men with hypogonadism when used at therapeutic doses. [19]

Two findings from TRAVERSE warrant caution. Atrial fibrillation was more common in the testosterone arm (3.5% vs. 2.4%; P<0.05). Acute kidney injury was also numerically higher. [11] These signals require discussion with patients who already carry atrial fibrillation risk factors.

When TRT Is Not the Answer

Not every man with low testosterone needs or benefits from TRT. Men with total testosterone between 200 to 300 ng/dL and no symptoms should generally not be treated. Men with active prostate cancer, breast cancer, a hematocrit above 54%, or untreated severe obstructive sleep apnea are contraindicated per Endocrine Society guidance. [1]

Men with secondary hypogonadism from obesity may recover normal testosterone through weight loss alone. A 10 to 15% weight reduction can raise testosterone by 100 to 150 ng/dL in this population. [7] Men on opioids may recover function after opioid tapering or rotation to buprenorphine. Men with hyperprolactinemia from a microprolactinoma typically normalize testosterone within 3 months of cabergoline 0.5 mg twice weekly. [6]

The Endocrine Society guideline states: "We suggest against making a general population diagnosis of androgen deficiency or offering testosterone therapy in men who do not have symptoms and signs of androgen deficiency." [1] That statement cuts against the direct-to-consumer TRT marketing that treats a lab value in isolation.